Abstract
Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissues structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.
Keywords: Epicardial adipose tissue, epicardial fat, cardiac adiposity, echocardiography, therapeutic target
Current Pharmaceutical Design
Title: Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Gianluca Iacobellis and Arya M. Sharma
Affiliation:
Keywords: Epicardial adipose tissue, epicardial fat, cardiac adiposity, echocardiography, therapeutic target
Abstract: Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissues structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.
Export Options
About this article
Cite this article as:
Gianluca Iacobellis and Arya M. Sharma , Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039670
DOI https://dx.doi.org/10.2174/138161207781039670 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracranial Aneurysms; In Need of Early Diagnostic and Treatment Using Bio- and Nanotechnology
Current Medicinal Chemistry Reversal of Diabetes and Metabolic Disorders After Bariatric Surgery
Current Nutrition & Food Science Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Biodegradable Composite Scaffolds: A Strategy to Modulate Stem Cell Behaviour
Recent Patents on Drug Delivery & Formulation Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design The Postprandial State and its Influence on the Development of Atherosclerosis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Fibrin Clot Properties and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Hormone Therapy and Delivery Strategies against Cardiovascular Diseases
Current Pharmaceutical Biotechnology Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Innovative Stride to Zero Hunger Beyond 2015 in Nigeria
Recent Patents on Food, Nutrition & Agriculture Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Current Psychopharmacology Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design